Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer

TOMOHIRO HIRANO1, KUNITAKA HIROSE2, KENICHI SAKURAI3, MAKOTO MAKISHIMA3, KENJI SASAKI3 and SADAO AMANO1

1Division of Breast and Endocrine Surgery, Department of Surgery, 2Division of Biomedical Sciences and 3Division of Plastic and Reconstructive Surgery, Department of Plastic and Reconstructive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan; 2Biomedical Research Laboratory, Kureha Chemical Industry Co., Ltd., Shinjuku-ku, Tokyo, Japan

Abstract. Background: A disintegrin and metalloproteinase with thrombospondin motifs-1 (ADAMTS1), a member of the ADAMTS family of proteases, is involved in the shedding of epidermal growth factor (EGF)-like ligands such as amphiregulin, which activate the EGF receptor. Since ADAMTS1 has been implicated in aggressive breast carcinogenesis, we examined potential antitumor effects of antibody to ADAMTS1 in a mouse model of breast cancer. Materials and Methods: BALB/c female mice were inoculated with syngenic 4T1 breast cancer cells and treated with anti-ADAMTS1 antibody or control IgG. Tumor volume and weight were evaluated. Results: Mouse 4T1 cells expressed ADAMTS1 and its substrates amphiregulin and heparin-binding EGF. Treatment with antibody to ADAMTS1 inhibited tumor growth without any adverse effects. Conclusion: ADAMTS1 could be a promising molecular target for immunotherapy of breast cancer.

A disintegrin and metalloproteinase with thrombospondin motifs-1 (ADAMTS1), a member of the ADAMTS family of proteases (1), is composed of propeptide, metalloproteinase, disintegrin, and cysteine-rich domains, domains containing thrombospondin type I-like motifs, and a spacer region (2). ADAMTS1 has been shown to be up-regulated in breast cancer cell lines with elevated metastatic activity (3). Overexpression of ADAMTS1 promotes pulmonary metastasis of TA3 mammary carcinoma and Lewis lung carcinoma cells (4). ADAMTS1 and matrix metalloproteinase-1 synergistically promote bone metastasis of breast cancer cells by shedding epidermal growth factor (EGF)-like ligands, including heparin-binding EGF (HB-EGF), amphiregulin, and transforming growth factor α, from tumor cells, and subsequent activation of the EGF receptor (EGFR) (5). In human breast samples, ADAMTS1 mRNA is expressed in non-neoplastic mammary tissues, predominantly in stromal fibroblasts, and is significantly down-regulated in breast carcinomas (6). The erythroblastic leukemia viral oncogene homolog (ERBB) family of receptor tyrosine kinases, comprising EGFR (or ERBB1), ERBB2 (or HER2), ERBB3 and ERBB4, have been implicated in the development and progression of many types of human cancer, including breast cancer (7). EGF, transforming growth factor α and amphiregulin bind specifically to EGFR, while HB-EGF binds to both EGFR and ERBB4. None of the EGF family of peptides bind to ERBB2, and ERBB2 has been suggested to function in a dimer with other ERBB receptors. Amphiregulin and HB-EGF are up-regulated in breast cancer (8, 9). ADAMTS1 sheds amphiregulin and HB-EGF to soluble forms, and these EGF-like ligands can promote breast tumor growth and progression by functioning as autocrine and/or paracrine growth factors (4, 5). Several antibodies and tyrosine kinase inhibitors against ERBB receptors have been developed and some of them are effective breast cancer treatments (7). Since inhibition of ADAMTS1 activation or expression blocks EGFR signaling (4, 5), ADAMTS1 is suggested to be a promising target for breast cancer therapy. In this study, we examined the effects of an antibody to ADAMTS1 on tumor growth in a mouse model of breast cancer.

Materials and Methods

Cell culture. Murine breast cancer 4T1 cells (American Type Culture Collection, Manassas, VA, USA), derived from BALB/c mice (10), were culture in RPMI-1640 medium containing 10 mM 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid, 1 mM sodium

†Died September 20, 2009.

Correspondence to: Makoto Makishima, Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan. Tel/Fax: +81 339728199, e-mail: makishima.makoto@nihon-u.ac.jp

Key Words: Breast cancer, ADAMTS1, amphiregulin, xenograft, immunotherapy.

0250-7005/2011 $2.00+.40
pyruvate and 10% fetal bovine serum at 37˚C in a humidified 5% CO2 atmosphere.

Northern analysis. Total RNA from cells was prepared by guanidium isothiocyanate lysis followed by cesium chloride gradient ultracentrifugation and probed as described previously (11). cDNA probes included mouse amphiregulin (nucleotides 189-960; GenBank accession no. BC009138) and HB-EGF (nucleotides 222-909; GenBank accession no. NM_010415), which were generated from a mouse spleen cDNA library (OriGene Technologies, Inc., Rockville, MD, USA) by polymerase chain reaction and labeled with [α-32P]dCTP.

Western immunoblotting analysis. Total cell lysates (10 μg for each lane) from 4T1 cells were electrophoresed on a sodium dodecyl sulfate-polyacrylamide gel and transferred to a polyvinylidene fluoride membrane for immunoblotting. Western blot analysis was performed using antibodies to ADAMTS1 (Sigma-Aldrich, St. Louis, MO, USA), amphiregulin (Thermo Fisher Scientific Inc., Rockford, IL, USA), or β-actin (Sigma-Aldrich), visualized with an ECL Plus detection system (GE Healthcare, Chalfont St. Giles, UK).

Production of antibody to ADAMTS1. Full-length cDNA encoding mouse ADAMTS1 (2) was inserted into pcDNA3.1 with histidine and flag tags at the C-terminal site. Recombinant ADAMTS1 protein was expressed in HEK293T cells (American Type Culture Collection) and purified with a nickel column. New Zealand White rabbits (Oriental Yeast Co., Ltd., Tokyo, Japan) were immunized subcutaneously with ADAMTS1 repeatedly. The antiserum was obtained 38 days after immunization and purified with a Protein A Sepharose column chromatography (GE Healthcare).

Animal studies. Six-week-old BALB/c female mice (CLEA Japan, Inc., Tokyo, Japan) were inoculated subcutaneously with 4T1 cells (1×10⁶). Starting the next day, mice were injected with anti-ADAMTS1 antibody or control IgG (100 μg) via the tail vein twice a week (n=7 per group), and body weights and tumor volumes were measured as described previously (11). All animal experiments were conducted in accordance with Animal Care and Use Committee guidelines of Kureha Chemical Industry and Japanese governmental guidelines for animal experiments.

Results

We first examined the expression of ADAMTS1 in breast cancer 4T1 cells, which are aggressive and can metastasize to bone and other tissues (12). As reported in human breast cancer cells with highly metastatic activity (3), ADAMTS1 was detected in 4T1 cells (Figure 1A). Amphiregulin and HB-EGF are EGF-like ligands that are shed and activated by ADAMTS1 (4, 5). 4T1 cells produced amphiregulin protein (Figure 1A). Expression of amphiregulin and HB-EGF mRNA was also detected in 4T1 cells (Figure 1A and B).

We determined the effects of anti-ADAMTS1 antibody on tumor growth of 4T1 cells in syngenic BALB/c mice. Tumor
formation was detected in all the mice inoculated with 4T1 cells at day 3 (Figure 2A). Treatment with anti-ADAMTS1 antibody tended to inhibit tumor growth at day 7 and day 10 and exhibited a significant inhibition at day 14 when compared to the control antibody (Figure 2A). A similar trend was observed at day 17 although it was at the limit of significance ($p=0.057$). Tumor weight at day 17 in mice treated with anti-ADAMTS antibody was significantly decreased, being 0.77±0.13 g, which was 63% that of control mice (1.23±0.41 g) (Figure 2B). Although abnormal phenotypes of ADAMTS1-null mice indicate the existence of a physiological function of ADAMTS1 (13), mice treated with anti-ADAMTS1 antibody gained body weight as well as control mice (Figure 2C) and did not exhibit any adverse reactions to treatment.

**Discussion**

ADAMTS1 is expressed in both metastatic breast cancer cells and normal mammary tissues (6, 14). EGF-like ligands, including amphiregulin and HB-EGF, are substrates of ADAMTS1 and soluble forms of these ligands play a role in bone metastasis of breast cancer (5). Amphiregulin is required for mammary gland development (15), and activation of ERBB receptors is involved in breast carcinogenesis (16). 4T1 breast cancer cells expressed ADAMTS1, amphiregulin and HB-EGF (Figure 1). 4T1 cells also express EGFR and treatment with EGF induces strong phosphorylation of EGFR and extracellular regulated protein kinase (17). Overexpression of ADAMTS1 increases phosphorylation of EGFR and ERBB2 in a protease-dependent manner (4). Our results show that treatment with antibody to ADAMTS1 suppressed tumor growth of 4T1 cells in mice (Figure 2), suggesting that the antibody used here inhibits ADAMTS1 functions, such as the shedding of amphiregulin and/or HB-EGF and subsequent activation of ERBB receptors. Amphiregulin is also cleaved by other proteases such as ADAM17 (18). Further studies are needed to determine whether antibody to ADAMTS1 can inhibit function of other ADAM and ADAMTS proteases. ADAMTS1 promotes cancer cell migration by modulating the extracellular matrix and inducing a stromal reaction (19, 20). The antibody to ADAMTS1 may inhibit tumor growth and progression by multiple mechanisms. The underlying molecular and cellular mechanisms remain to be elucidated. In addition to the successful use of ERBB-targeted antibodies such as trastuzumab, immunotherapy against ADAMTS1 might be promising in the treatment of breast cancer.

**Acknowledgements**

The Authors thank Drs. Mayumi Aoki-Asai, Hirobumi Asai and Mitsunori Hakozaki of Biomedical Research Laboratory, Kureha Chemical Industry for technical assistance and helpful comments, and Dr. Andrew I. Shulman for editorial assistance.

**Figure 2.** Effect of antibody to ADAMTS1 on tumor growth of 4T1 cells in xenografts. A: Time course of tumor volume. B: Tumor weight at day 17. C: Body weight. BALB/c female mice inoculated with syngenic breast cancer 4T1 cells were treated with control antibody (Control) or antibody to ADAMTS1 (anti-ADAMTS1) as described in the Materials and Methods. *p<0.05 compared with control, one-way ANOVA.
References


Received August 10, 2011
Revised October 3, 2011
Accepted October 5, 2011